Latest Sham surgery Stories
Investigators at The Feinstein Institute for Medical Research have utilized a new image-based strategy to identify and measure placebo effects in randomized clinical trials for brain disorders.
A scale developed to measure the potential harm caused by invasive placebos in local anaesthesia research has been successfully tested by a group of 43 independent clinicians.
FORT LEE, N.J., June 8, 2011 /PRNewswire/ -- Neurologix, Inc.
A multi-center gene therapy trial for patients with advanced Parkinsonâ€™s disease demonstrated reduced symptoms of the progressive movement disorder, according to a new study published in Lancet Neurology.
A first-of-its-kind study of gene therapy in the treatment of Parkinson's disease determined that half of all patients who received the treatment had "clinically meaningful improvements" of their symptoms within six months of surgery.
A gene therapy called NLX-P101 dramatically reduces movement impairment in Parkinson's patients.
FORT LEE, N.J., March 16, 2011 /PRNewswire/ -- Neurologix, Inc.
SAN DIEGO, Feb. 3, 2011 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical company, announced today that it is progressing with enrollment and dosing in its CERE-120 (AAV2-neurturin) Phase 2b multi-center, sham-surgery, double-blinded controlled trial in Parkinson's disease.
Neurologix has received institutional review board approvals to begin recruiting and enrolling participants for its Phase II clinical trial of the company's gene transfer approach to the treatment of advanced Parkinson's disease.
Titan Pharmaceuticals, Inc.
- To fire mitraille at.